The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.
Zev A. Wainberg
No relevant relationships to disclose
Saeed Rafii
No relevant relationships to disclose
Ramesh K. Ramanathan
Honoraria - Biomarin
Research Funding - Biomarin
Lida A. Mina
No relevant relationships to disclose
Lauren Averett Byers
No relevant relationships to disclose
Rashmi Chugh
Research Funding - Biomarin
Jonathan Wade Goldman
No relevant relationships to disclose
Jasgit C. Sachdev
No relevant relationships to disclose
Daniela E. Matei
No relevant relationships to disclose
Jennifer J. Wheler
No relevant relationships to disclose
Joshua W. Henshaw
Employment or Leadership Position - Biomarin
Charlie Zhang
Employment or Leadership Position - Biomarin
Gilles Gallant
Employment or Leadership Position - Biomarin
Stock Ownership - Biomarin
Johann Sebastian De Bono
No relevant relationships to disclose